| Popis: |
Abstract Background & aim: The vascular endothelial growth factor of the tumor, which binds to its receptors at the level of endothelial cells, plays an important role in vascular permeability and tumor angiogenesis. In the present study, a vascular endothelial cell growth factor antagonist peptide (VEGF) was designed with the goal of inhibiting the desired peptide (VGB4) interfering with endothelial growth factor receptors in its receptors, thereby inhibiting the signaling pathways angiogenesis. Methods: In the present experimental study, 42 female Balb / C mice (4 to 6 weeks old) with an average weight of 20 grams were used. Tissue cell line 4T1 was used to model breast cancer. It turned out after subcutaneous transplantation of mammary tumors in animals, daily intraperitoneal injection of different doses of VGB4 peptide (10, 5, 2.5, 1, 0.25 mg / kg) for 14 days, and the antitumor potential of different peptide concentrations during the injection period compared to the control was statistically analyzed. Data were analyzed by ANOVA and Duncan tests. Results: Increasing the doses of peptide reduced the tumor growth in treated groups, but no significant inhibitory effect was seen on tumor growth by increasing the dose from 5 mg / kg to 10 mg / kg. Therefore, the dose of 5 mg / kg is the best anti-tumor dose of the VGB4 peptide. Conclusion: VGB4 peptide had a significant inhibitory effect on the growth of breast cancer carcinoma of the 4T1 cell line. Due to the effects of VIT4 antitumor, it may be possible to use this peptide for cancer treatment in the future. |
